You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 45 No. 8, August 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Thiamine and Alzheimer's Disease

A Pilot Study

John P. Blass, MD, PhD; Patricia Gleason, BSN; Dorothea Brush, MSG; Pompeo DiPonte, DPharm; Howard Thaler, PhD

Arch Neurol. 1988;45(8):833-835.


Abstract

• As a test of the significance of previously described biochemical abnormalities in thiamine-dependent enzymes in brains and other tissues in patients with Alzheimer's disease, a double-blind, placebo-controlled, crossover, outpatient pilot study compared the effects of 3 g/d of oral thiamine hydrochloride for three months with those of a niacinamide placebo. Eleven moderately impaired patients with "probable Alzheimer's disease" by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria completed the study. All patients were well nourished and had no stigmata of dietary thiamine deficiency. Their initial mean ± SEM Mini-Mental State Examination score was 14.2 ± 1.4, and the mean age was 72 years. Global cognitive rating by the Mini-Mental State Examination was higher during three months with 3 g/d of oral thiamine hydrochloride than with niacinamide placebo. Behavioral ratings, however, did not differ significantly, nor did clinical state when it was judged subjectively.



Author Affiliations

From the Will Rogers Institute and the Dementia Research Service, Cornell University Medical College, Burke Rehabilitation Center, White Plains, NY.


Footnotes

Accepted for publication Feb 15, 1988.

Reprint requests to Dementia Research Service, Burke Rehabilitation Center, 785 Mamaroneck Ave, White Plains, NY 10605 (Dr Blass).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives.
Lonsdale
Evid Based Complement Alternat Med 2006;3:49-59.
ABSTRACT | FULL TEXT  

Plasma and Red Blood Cell Thiamine Deficiency in Patients With Dementia of the Alzheimer's Type
Gold et al.
Arch Neurol 1995;52:1081-1086.
ABSTRACT  

Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review
Patel
J Geriatr Psychiatry Neurol 1995;8:81-95.
ABSTRACT  

Preliminary Findings of High-Dose Thiamine in Dementia of Alzheimer's Type
Meador et al.
J Geriatr Psychiatry Neurol 1993;6:222-229.
ABSTRACT  

Drug Treatment of Alzheimer's Disease
Cooper
Arch Intern Med 1991;151:245-249.
ABSTRACT  

A Trial of Thiamine in Alzheimer's Disease
Nolan et al.
Arch Neurol 1991;48:81-83.
ABSTRACT  

Studies of Transketolase Abnormality in Alzheimer's Disease
Sheu et al.
Arch Neurol 1988;45:841-845.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.